Pavel Mozgunov (P Mozgunov)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 26

Top Topics

Chronic Obstructive Pulmonary Disease

Top Venues

Statistics in medicine

Statistical methods in medical research

Biometrical journal. Biometrische Zeitschrift

Journal of biopharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research (2024)
Peter Greenstreet, Thomas F Jaki, Alun Bedding, Chris Harbron, Pavel Mozgunov
A multi-arm multistage platform design that allows preplanned addition of arms while still controlling the family-wise error. Statistics in medicine (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
Peter Greenstreet, Thomas F Jaki, Alun Bedding, Chris Harbron, Pavel Mozgunov
A multi-arm multi-stage platform design that allows preplanned addition of arms while still controlling the family-wise error. Statistics in medicine 43 (19) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki
A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering. Statistics in medicine (2023)
Libby Daniells, Pavel Mozgunov, Alun Bedding, Thomas F Jaki
A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method. Statistics in medicine (2023)
Alessandra Serra, Pavel Mozgunov, Geraint Davies, Thomas Jaki
Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial design. Pharmaceutical statistics (2023)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki
A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering. Statistics in medicine (2023)
Haiyan Zheng, Michael J Grayling, Pavel Mozgunov, Thomas Jaki, James M S Wason
Bayesian sample size determination in basket trials borrowing information between subsets. Biostatistics (Oxford, England) (2022)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki
An order restricted multi-arm multi-stage clinical trial design. Statistics in medicine 41 (9) (2022)
Tom Menzies, Gaelle Saint-Hilary, Pavel Mozgunov
A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment. Statistical methods in medical research 31 (5) (2022)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki, Fabio Rigat
What is the expected benefit of patient-centric clinical development in oncology? Journal of biopharmaceutical statistics 32 (3) (2022)
Pavel Mozgunov, Thomas F Jaki, Ioannis Gounaris, Thomas Goddemeier, Anja Victor, Marianna Grinberg
Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial. Statistics in medicine (2022)
Pavel Mozgunov, Suzie Cro, Anne Lingford-Hughes, Louise M Paterson, Thomas F Jaki
A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial. Pharmaceutical statistics (2021)
Pavel Mozgunov, Rochelle Knight, Helen Barnett, Thomas F Jaki
Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study. International journal of environmental research and public health 18 (1) (2021)
Pavel Mozgunov, Thomas Jaki, Xavier Paoletti
Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies. Biometrical journal. Biometrische Zeitschrift 62 (7) (2020)
Rachid Abbas, Caroline Rossoni, Thomas Jaki, Xavier Paoletti, Pavel Mozgunov
A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation. Clinical trials (London, England) 17 (5) (2020)
Pavel Mozgunov, Mauro Gasparini, Thomas Jaki
A surface-free design for phase I dual-agent combination trials. Statistical methods in medical research 29 (10) (2020)
Nigel Stallard, Lisa Hampson, Norbert Benda, Werner Brannath, Thomas Burnett, Tim Friede, Peter K Kimani, Franz Koenig, Johannes Krisam, Pavel Mozgunov, Martin Posch, James M S Wason, Gernot Wassmer, John Whitehead, S Faye Williamson, Sarah Zohar, Thomas F Jaki
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in biopharmaceutical research 12 (4) (2020)
Pavel Mozgunov, Thomas Jaki
Improving safety of the continual reassessment method via a modified allocation rule. Statistics in medicine 39 (7) (2019)
Pavel Mozgunov, T Jaki, M Gasparini
Loss functions in restricted parameter spaces and their Bayesian applications. Journal of applied statistics 46 (13) (2019)
Pavel Mozgunov, Thomas Jaki
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints. Biometrical journal. Biometrische Zeitschrift 61 (6) (2019)
Pavel Mozgunov, Thomas F Jaki, Xavier Paoletti
Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. Journal of biopharmaceutical statistics 29 (2) (2018)